# Prognostic Factors for Survival in Glioblastoma: A Retrospective Analysis Focused on the Role of Hemoglobin

**Authors:** Zuzana Pleskacova, Michael Bartos, Hana Vosmikova, Rafael Dolezal, Petr Krupa, Barbora Vitovcova, Petra Kasparova, Emil Rudolf, Veronika Skarkova, Denisa Pohankova, Veronika Novotna, Jiri Petera

PMC · DOI: 10.3390/biomedicines12061210 · 2024-05-29

## TL;DR

This study analyzed survival factors in glioblastoma patients and found that hemoglobin levels were not significant predictors of survival or HIF-1α expression.

## Contribution

The study confirms that hemoglobin levels are not a significant prognostic factor in glioblastoma, despite their potential role in hypoxia.

## Key findings

- Four variables—age, extent of surgery, HIF-1α expression, and epilepsy—were significant prognostic factors for survival.
- Hemoglobin levels were not significantly associated with survival or HIF-1α/HIF-1β expression.
- Median survival was 11.9 months among 136 glioblastoma patients.

## Abstract

Background: Although several prognostic factors for survival have been identified in glioblastoma, there are numerous other potential markers (such as hemoglobin) whose role has not yet been confirmed. The aim of this study was to evaluate a wide range of potential prognostic factors, including HIF-1α and hemoglobin levels, for survival in glioblastoma. A secondary aim was to determine whether hemoglobin levels were associated with HIF-1α expression. Methods: A retrospective study of 136 patients treated for glioblastoma at our institution between 2012 and 2021 was performed. Cox univariate and multivariate analyses were carried out. Kaplan–Meier survival curves were generated. In addition, bivariate non-parametric correlation analyses were performed for key variables. Results: Median survival was 11.9 months (range: 0–119.4). According to the univariate analysis, 13 variables were significantly associated with survival: age, performance status, extent of surgery, tumor depth, tumor size, epilepsy, postoperative chemoradiotherapy, IDH mutations, CD44, HIF-1α, HIF-1β, vimentin, and PDFGR. According to the multivariate regression analysis, only four variables remained significantly associated with survival: age, extent of surgery, epilepsy, and HIF-1α expression. No significant association was observed between hemoglobin levels (low <120 g/L in females or <140 g/L in males vs. high ≥120 or ≥140 g/L) and survival or HIF-1α/HIF-1β expression. Conclusions: In this retrospective study of patients with glioblastoma, four variables—age, extent of surgery, HIF-1α expression, and epilepsy—were significant prognostic factors for survival. Hemoglobin levels were not significantly associated with survival or HIF-1α expression. Although hypoxia is a well-recognized component of the glioblastoma microenvironment, more research is needed to understand the pathogenesis of onset tumor hypoxia and treatment implication.

## Linked entities

- **Genes:** IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417], CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], ARNT (aryl hydrocarbon receptor nuclear translocator) [NCBI Gene 405], PRELID1 (PRELI domain containing 1) [NCBI Gene 737446]
- **Diseases:** glioblastoma (MONDO:0018177)

## Full-text entities

- **Genes:** VIM (vimentin) [NCBI Gene 7431], IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}, ARNT (aryl hydrocarbon receptor nuclear translocator) [NCBI Gene 405] {aka ARNT1, HIF-1-beta, HIF-1beta, HIF1-beta, HIF1B, HIF1BETA}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}
- **Diseases:** Glioblastoma (MESH:D005909), epilepsy (MESH:D004827), hypoxia (MESH:D000860), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11200864/full.md

---
Source: https://tomesphere.com/paper/PMC11200864